Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:CVKD NASDAQ:DARE NASDAQ:ENSC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.02-2.9%$0.91$0.57▼$3.15$34.24M0.36468,943 shs66,942 shsCVKDCadrenal Therapeutics$13.96+2.6%$12.77$8.74▼$22.90$27.87M0.9628,879 shs20,027 shsDAREDare Bioscience$2.29+2.2%$2.12$1.83▼$9.19$30.26M1.14128,335 shs141,249 shsENSCEnsysce Biosciences$2.46+1.7%$2.17$1.62▼$14.67$7.18M1.1109,185 shs873,884 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+2.44%+3.96%+28.25%-6.79%-65.46%CVKDCadrenal Therapeutics+0.59%-1.59%+2.79%+4.93%+13.42%DAREDare Bioscience-0.44%+6.67%+4.19%-8.20%-32.12%ENSCEnsysce Biosciences-0.41%+2.11%+13.62%+8.04%-26.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.02-2.9%$0.91$0.57▼$3.15$34.24M0.36468,943 shs66,942 shsCVKDCadrenal Therapeutics$13.96+2.6%$12.77$8.74▼$22.90$27.87M0.9628,879 shs20,027 shsDAREDare Bioscience$2.29+2.2%$2.12$1.83▼$9.19$30.26M1.14128,335 shs141,249 shsENSCEnsysce Biosciences$2.46+1.7%$2.17$1.62▼$14.67$7.18M1.1109,185 shs873,884 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+2.44%+3.96%+28.25%-6.79%-65.46%CVKDCadrenal Therapeutics+0.59%-1.59%+2.79%+4.93%+13.42%DAREDare Bioscience-0.44%+6.67%+4.19%-8.20%-32.12%ENSCEnsysce Biosciences-0.41%+2.11%+13.62%+8.04%-26.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 2.33Hold$3.30223.53% UpsideCVKDCadrenal Therapeutics 2.00Hold$32.00129.23% UpsideDAREDare Bioscience 2.33Hold$10.00336.68% UpsideENSCEnsysce Biosciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ENSC, AKTX, DARE, and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CVKDCadrenal TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025DAREDare BioscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ENSCEnsysce BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CVKDCadrenal TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DAREDare BioscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ENSCEnsysce BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/9/2025AKTXAkari TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.609/4/2025DAREDare BioscienceMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$8.007/18/2025AKTXAkari TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/ADAREDare Bioscience$10K3,086.92N/AN/A($0.69) per share-3.32ENSCEnsysce BiosciencesN/AN/AN/AN/A$2.59 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-78.03%-31.62%11/18/2025 (Estimated)CVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)DAREDare Bioscience-$4.05M-$2.14N/AN/AN/AN/AN/A-103.70%11/13/2025 (Estimated)ENSCEnsysce Biosciences-$7.99M-$4.03N/AN/AN/A-88.76%-167.23%-104.59%11/11/2025 (Estimated)Latest ENSC, AKTX, DARE, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DAREDare Bioscience-$0.55-$0.45+$0.10-$0.45$0.14 million($0.02) million8/13/2025Q2 2025ENSCEnsysce Biosciences-$1.02-$0.79+$0.23-$0.79$0.67 million$1.37 million8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.190.19CVKDCadrenal TherapeuticsN/A3.553.55DAREDare BioscienceN/A0.340.34ENSCEnsysce BiosciencesN/A2.102.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%CVKDCadrenal Therapeutics7.92%DAREDare Bioscience6.70%ENSCEnsysce Biosciences5.63%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%CVKDCadrenal Therapeutics26.09%DAREDare Bioscience4.80%ENSCEnsysce Biosciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.62 million20.19 millionNot OptionableCVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableDAREDare Bioscience3013.48 million12.83 millionNot OptionableENSCEnsysce Biosciences102.97 million2.73 millionNot OptionableENSC, AKTX, DARE, and CVKD HeadlinesRecent News About These CompaniesEnsysce Biosciences shares key takeaways from PAINWeek symposiumSeptember 4, 2025 | msn.comEnsysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 SymposiumSeptember 4, 2025 | accessnewswire.comAEnsysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025August 19, 2025 | accessnewswire.comADiamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)August 15, 2025 | globenewswire.comEnsysce Biosciences Narrows Loss in Q2August 14, 2025 | aol.comAENSC Focused on Bringing Change to Pain Relief MarketAugust 14, 2025 | msn.comEnsysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program UpdatesAugust 13, 2025 | accessnewswire.comAEnsysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA FeedbackJuly 31, 2025 | accessnewswire.comAENSC Start Phase 3 Trial on Abuse-Resistant Pain RelieverJuly 16, 2025 | finance.yahoo.comEnsysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce AbuseJuly 16, 2025 | accessnewswire.comAEnsysce Biosciences Inc News (ENSC) - Investing.comJuly 11, 2025 | investing.comEnsysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2June 24, 2025 | accessnewswire.comAEnsysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025June 11, 2025 | accessnewswire.comAensysce biosciences appoints baker tilly as new auditorJune 7, 2025 | investing.comEnsysce Flat on Receiving GrantJune 4, 2025 | baystreet.caEnsysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose ProtectionJune 4, 2025 | accessnewswire.comAENSC is Moving Closer to Changing the Pain Relief MarketMay 14, 2025 | finance.yahoo.comEnsysce Biosciences Shares Jump After Receiving Patent, Reporting 1Q ResultsMay 14, 2025 | marketwatch.comEnsysce Biosciences Reports First Quarter 2025 Financial ResultsMay 13, 2025 | accessnewswire.comAEnsysce Biosciences Bolsters Management Team with Regulatory ExpertMay 12, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeENSC, AKTX, DARE, and CVKD Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.02 -0.03 (-2.86%) Closing price 03:59 PM EasternExtended Trading$1.02 0.00 (0.00%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Cadrenal Therapeutics NASDAQ:CVKD$13.96 +0.35 (+2.57%) Closing price 04:00 PM EasternExtended Trading$13.93 -0.03 (-0.21%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Dare Bioscience NASDAQ:DARE$2.29 +0.05 (+2.23%) Closing price 04:00 PM EasternExtended Trading$2.30 +0.00 (+0.22%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Ensysce Biosciences NASDAQ:ENSC$2.46 +0.04 (+1.65%) Closing price 04:00 PM EasternExtended Trading$2.48 +0.02 (+0.81%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Falcon Flex Drives Growth as CrowdStrike Bets on AI Security Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
